Follow-up gene therapy study for MPS IIIA participants
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This follow-up study looks at how a past gene therapy treatment (UX111) is affecting you over time. It mainly involves continued visits and safety checks, and it helps researchers understand long-term benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in an earlier study where you received UX111
- A parent or legal guardian must be willing and able to review and sign consent
- You (and your caregiver) must be able to follow the study visit schedule
- You cannot be joining another study that could interfere with measuring UX111’s safety or effects
- You must not have any other health situation that makes the required study procedures impossible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This trial tests a new medicine called GC1130A for children with Sanfilippo syndrome type A (MPS IIIA). The goal is to see if it is safe and if it might help with symptoms.
This study follows people with MPS IIIC (Sanfilippo syndrome type C) over time to understand how the disease changes. It does not test a new treatment, but helps researchers learn more about the condition, which could lead to better care in the future.
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
This trial tests an experimental drug, JR-446, for children with Sanfilippo syndrome type B (MPS IIIB). The goal is to see if it is safe and can help with symptoms.
Hear when a new Sanfilippo Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.